Meeting
2023 ASCO Annual Meeting
A phase II study of lenvatinib plus pembrolizumab in patients with progressive, recurrent/metastatic adenoid cystic carcinoma.
Authors
Maliheh Mohamadpour
MSKCC, New York, NY
Maliheh Mohamadpour , Eric Jeffrey Sherman , Anuja Kriplani , James Vincent Fetten , Lara Dunn , Loren S. Michel , Kin Wai (Tony) Hung , Shrujal S. Baxi , Erin McDonald , Rachel Conybeare , Nora Katabi , Irina Ostrovnaya , David G. Pfister , Alan Loh Ho
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT04209660
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 6048)
DOI
10.1200/JCO.2023.41.16_suppl.6048
Abstract #
6048
Poster Bd #
40
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A phase II study of pemetrexed and pembrolizumab in recurrent and/or metastatic salivary gland malignancies.
First Author: Katharine Andress Rowe Price
Poster
2020 ASCO Virtual Scientific Program
A phase II study on the efficacy and toxicity of cabozantinib in recurrent/metastatic salivary gland cancer patients.
First Author: Wim van Boxtel
Poster
2023 ASCO Annual Meeting
Phase II study evaluating the efficacy of niraparib and dostarlimab (TSR-042) in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) patients.
First Author: Olga Zamulko
Poster
2023 ASCO Annual Meeting
PLUME: A single-arm phase II trial evaluating the combination of pembrolizumab and lenvatinib in metastatic uveal melanoma (mUM) patients (pts) previously treated or not with tebentafusp.
First Author: Manuel Rodrigues